Introduction
============

Cancer-related deaths continue to rise in both developed and developing countries. In 2012, there were about 14.1 million new cancer cases and 8.2 million cancer-related deaths all over the world. Lung and breast cancer are the most common forms of cancer in human beings. Moreover, the incidences of liver, stomach and colorectal cancer are also very high in men and stomach, while cervix uteri and colorectal cancer prevail in women. Cancer is a complex disease. A variety of cancer risk factors have been recognized, such as smoking, drinking, lack of exercise, poor diet, reproductive changes, and genetic lesions \[[@r1]\]. Inherited genetic causations of cancer risk are mainly unidentified. Thus far, great effects have been made to discover genetic variant alleles implicated in the crucial signaling pathways, which may influence individual cancer predisposition.

Genetic DNAs of living organisms are constantly subjected to various types of damages caused by environmental agents and byproducts (e.g., reactive oxygen species) of cellular metabolic processes. To maintain genome integrity, human beings possess a number of systems for the prevention and restoration of DNA damage. Reduced DNA repair ability is a predisposing factor to cancer \[[@r2]\]. Five common DNA repair pathways have been identified, including nucleotide excision repair (NER), base excision repair, double-strand DNA break repair, mismatch repair, and transcription coupled repair \[[@r3],[@r4]\]. Among these pathways, NER is responsible for removing damaged DNA fragments (e.g., bulky adducts) resulting from radiation or chemical agents \[[@r5],[@r6]\]. In the NER pathway, at least eight vital genes \[*excision repair cross-complementation group 1* (*ERCC1*), *ERCC2/ Xeroderma pigmentosum group D* (*XPD*), *ERCC3/XPB*, *ERCC4/XPF*, *ERCC5/XPG*, *XPA*, *XPC* and *XPE*/*damaged DNA-binding protein 1* (*DDB1*)\] have been well studied, which participate in DNA repair, capable of preserving genetic integrity to prevent cells from malignant transformation \[[@r7]\].

*ERCC5/XPG* is located on chromosome 13q22-33, consisting of 15 exons and 14 introns . Its protein product is a 1,186 amino acid structure-specific endonuclease, and plays an essential role in the two incision steps of NER \[[@r4],[@r8]\]. *XPG* is highly polymorphic. Among known single nucleotide polymorphisms (SNPs) in this gene, a nonsynonymous Asp1104His (rs17655, G\>C) polymorphism is most frequently studied for its association with cancer risk \[[@r2],[@r9]--[@r38]\]. However the results are inconsistent from study to study. Therefore, we performed this meta-analysis with all eligible publications to investigate the association between the *XPG* gene rs17655 G\>C polymorphism and cancer risk.

RESULTS
=======

Study characteristics
---------------------

As shown in [Figure 1](#f1){ref-type="fig"}, we found 362 potentially relevant studies from PubMed, EMBASE, CNKI, WANFANG, and Vip databases. After reviewing titles and abstracts, we excluded 281 publications not investigating the association between *XPG* gene rs17655 polymorphism and cancer risk. And then, full texts of remaining articles were evaluated. Two publications \[[@r39],[@r40]\] were removed for containing overlap data. We also excluded 11 publications \[[@r41]--[@r51]\] because no sufficient data were reported to calculate ORs and 95% CIs. Furthermore, we eliminated five publications \[[@r52]--[@r56]\] presenting survival data only. At last, we excluded five publications \[[@r57]--[@r61]\] due to deviation from HWE. In the end, 58 publications with a total of 27,098 cancer cases and 30,535 healthy controls were included in the meta-analysis. It was noteworthy that, 58 publications actually consisted of 60 case-control studies, because 2 of them included two individual studies. The characteristics of these studies were showed in [Table 1](#t1){ref-type="table"}. Among these publications, five focused on gastric cancer \[[@r15],[@r22],[@r31],[@r37],[@r38]\], 10 on breast cancer \[[@r18],[@r29],[@r33],[@r34],[@r59],[@r62]--[@r66]\], four on colorectal cancer \[[@r16],[@r20],[@r25],[@r67]\], four on lymphoma \[[@r11],[@r21],[@r68],[@r69]\], six on bladder cancer \[[@r24],[@r70]--[@r74]\], five on lung cancer \[[@r17],[@r30],[@r75]--[@r77]\], eight on skin cancer \[[@r14],[@r23],[@r26],[@r32],[@r35],[@r78]--[@r80]\], three on HNC \[[@r10],[@r81],[@r82]\], two on endometrial cancer \[[@r19],[@r83]\], laryngeal carcinoma \[[@r9],[@r84]\], and prostate cancer \[[@r12],[@r28]\]. Moreover, there was only one study for each of the following cancers: osteosarcoma \[[@r13]\], hepatocellular carcinoma \[[@r36]\], esophageal carcinoma \[[@r85]\], oral squamous cell carcinoma \[[@r86]\], sarcoma \[[@r2]\], cervical carcinoma \[[@r27]\] and brain cancer \[[@r87]\]. Among these case-control studies, 25 of them had quality scores higher than 9, while 35 had quality scores no more than 9. Finally, this meta-analysis contained 26 hospital-based, 31 population-based, and three mixed control studies.

![Flowchart of included publications.](aging-10-101448-g001){#f1}

###### Characteristics of included studies in the final meta-analysis.

  ------------------ ------ -------------- --------------------------- ------------------ -------- ---------------------------- ------ --------- ----- ------ ------- ------ ----- ------ ------ ------- ----
  Name               Year   Cancer type    Region                      Ethnicity          Design   Genotype                     Case   Control   MAF   HWE    Score                                      
                                                                                                   method                       GG     CG        CC    All    GG      CG     CC    All                   
  Feng               2016   Gastric        China                       Asian              HB       PCR-RFLP                     47     85        45    177    84      107    46    237    0.42   0.260   6
  Ma                 2016   Breast         China                       Asian              HB       PCR-RFLP                     116    145       59    320    84      107    46    237    0.42   0.260   7
  Du                 2016   Colorectal     China                       Asian              HB       TaqMan                       286    459       133   878    355     405    124   884    0.37   0.623   9
  Wang               2015   Breast         China                       Asian              HB       PCR-RFLP                     95     6         0     101    100     1      0     101    0.00   0.960   9
  Bahceci            2014   B-NHL          Turkey                      Others             PB       AS-PCR                       59     33        1     93     43      44     9     96     0.32   0.637   4
  Li                 2014   Gastric        China                       Asian              HB       PCR-RFLP                     99     83        36    218    112     82     24    218    0.30   0.135   7
  Zhu                2014   Bladder        China                       Asian              HB       MassARRAY                    62     160       65    287    76      139    67    282    0.48   0.825   6
  Lu                 2014   Larynx         China                       Asian              HB       MassARRAY                    53     69        54    176    78      63     36    177    0.38   0.001   8
  Liu                2014   Gastric        China                       Asian              HB       PCR-RFLP                     99     100       39    238    120     95     23    238    0.30   0.510   8
  Ruiz-Cosano        2013   BCL            Spain                       Caucasian          PB       TaqMan                       125    71        17    213    119     81     14    214    0.25   0.965   7
  Zeng               2013   Lung           China                       Asian              HB       PCR-RFLP                     15     77        47    139    35      61     37    133    0.51   0.341   8
  Yuan               2012   HNC            China                       Asian              PB       TaqMan                       108    191       95    393    234     433    217   884    0.49   0.552   12
  Biason             2012   Osteosarcoma   Italy                       Caucasian          HB       PCR-RFLP                     75     39        16    130    141     94     15    250    0.25   0.899   8
  Gil                2012   Colorectal     Poland                      Caucasian          HB       PCR-RFLP                     86     35        11    132    64      31     5     100    0.21   0.625   6
  Berhane            2012   Prostate       India                       Asian              PB       PCR-RFLP                     58     72        20    150    66      75     9     150    0.31   0.039   8
  Ma                 2012   HNC            America                     Caucasian          PB       SNPlex                       648    359       52    1059   654     350    62    1066   0.22   0.099   10
  Rouissi            2011   Bladder        Tunisia                     African            PB       PCR                          48     56        21    125    46      61     18    125    0.39   0.758   6
  Ibarrola-Villava   2011   Melanoma       Spain                       Caucasian          HB       TaqMan                       326    222       50    598    215     140    24    379    0.25   0.85    5
  Canbay             2011   Colorectal     Turkey                      Others             PB       PCR-RFLP                     43     34        2     79     148     83     16    247    0.23   0.352   10
  Goncalves          2011   Melanoma       Brazil                      Caucasian          HB       PCR-RFLP                     105    77        10    192    109     74     25    208    0.30   0.031   9
  Doherty            2011   Endometrial    America                     Others             PB       Unknown                      418    254       42    714    408     248    47    703    0.24   0.268   10
  Hsu                2010   Breast         China                       Asian              HB       TaqMan                       76     191       134   401    129     243    159   531    0.53   0.059   8
  Figl               2010   Melanoma       German, Spain               Caucasian          PB       TaqMan                       703    409       74    1186   725     465    84    1274   0.25   0.420   8
  Canbay             2010   Gastric        Turkey                      Others             PB       PCR-RFLP                     25     12        3     40     148     83     16    247    0.23   0.352   8
  Li                 2010   HCC            China                       Asian              HB       TaqMan                       174    233       93    500    151     265    91    507    0.44   0.175   11
  Narter             2009   Bladder        Turkey                      Others             PB       PCR-RFLP                     25     28        3     56     18      19     3     40     0.31   0.505   5
  Abbasi             2009   Larynx         Germany                     Caucasian          PB       Real-time PCR                137    103       8     248    380     230    37    647    0.23   0.778   11
  Hussain            2009   Gastric        China                       Asian              PB       SNPlex                       38     105       38    181    90      180    90    360    0.50   1.000   12
  El-Zein            2009   HD             America                     Caucasian          PB       TaqMan                       104    78        16    198    127     80     12    219    0.24   0.897   10
  McKean-Cowdin      2009   Brain          America                     Caucasian          Mixed    TaqMan and MassARRAY         499    348       157   1004   989     657    311   1957   0.33   0.000   13
  Pan                2009   Esophageal     America                     Caucasian          HB       TaqMan                       201    131       12    344    287     155    15    457    0.20   0.281   7
  Rajaraman          2008   Breast         America                     Others             PB       TaqMan                       482    288       49    819    674     352    53    1079   0.21   0.423   13
  Chang              2008   Lung           America                     Africa American    PB       Illumina                     68     119       68    255    93      138    49    280    0.42   0.858   8
  Chang              2008   Lung           America                     Latino             PB       Illumina                     60     44        9     113    138     127    34    299    0.33   0.561   7
  Pardini            2008   Colorectal     Czech                       Caucasian          HB       PCR-RFLP                     334    177       21    532    356     153    23    532    0.19   0.211   11
  Smith              2008   Breast         America                     African American   PB       MassARRAY                    13     32        7     52     18      37     20    75     0.51   0.913   9
  Hung               2008   Lung           World                       World              Mixed    Unknown                      1852   1155      209   3216   2485    1510   286   4281   0.24   0.006   10
  He                 2008   Cervical       China                       Asian              HB       mismatch amplification PCR   71     94        35    200    67      80     53    200    0.47   0.006   8
  Hooker             2008   Prostate       America                     African            HB       PCR                          74     119       61    254    99      142    60    301    0.44   0.484   8
  Wang               2007   NMSC           Texas                       Caucasian          HB       PCR                          146    89        11    246    200     119    10    329    0.21   0.121   8
  Povey              2007   Melanoma       Scotland                    Caucasian          PB       PCR-RFLP                     314    169       24    507    252     162    27    441    0.24   0.887   13
  Crew               2007   Breast         America                     Others             PB       Sequenom                     562    371       66    999    571     409    71    1051   0.26   0.846   11
  An                 2007   HNC            America                     Caucasian          HB       PCR                          507    286       36    829    519     289    46    854    0.22   0.489   11
  Jorgensen          2007   Breast         America                     Others             PB       TaqMan                       159    93        12    264    165     95     15    275    0.23   0.785   10
  Mechanic           2006   Breast         America                     African American   PB       TaqMan                       231    387       139   757    231     320    123   674    0.42   0.509   9
  Mechanic           2006   Breast         America                     Caucasian          PB       TaqMan                       771    409       69    1249   661     412    60    1133   0.23   0.685   9
  Shen               2006   Breast         America                     Others             PB       TaqMan                       83     63        8     154    82      62     7     151    0.25   0.268   11
  Sugimura           2006   OSCC           Japan                       Asian              HB       PCR-RFLP                     43     59        20    122    77      112    52    241    0.45   0.348   5
  Garcia-Closas      2006   Bladder        Spain                       Caucasian          HB       Sequencing                   629    434       78    1141   607     445    84    1136   0.27   0.844   11
  Li                 2006   Melanoma       America                     Caucasian          HB       PCR                          373    206       23    602    370     206    27    603    0.22   0.805   12
  Wu                 2006   Bladder        America                     Others             PB       TaqMan                       364    225       26    615    371     211    18    600    0.21   0.064   13
  Thirumaran         2006   BCC            Hungry, Romania, Slovakia   Caucasian          HB       TaqMan                       325    172       32    529    330     173    30    533    0.22   0.250   11
  Shen               2006   NHL            America                     Others             PB       TaqMan                       260    170       34    464    352     169    29    550    0.21   0.146   13
  Le Morvan          2006   Sarcoma        France                      Caucasian          HB       PCR-RFLP                     182    107       19    308    31      21     1     53     0.22   0.227   6
  Sakiyama           2005   Lung           Japan                       Asian              Mixed    Pyrosequencing               300    500       202   1002   228     333    124   685    0.42   0.900   7
  Shen               2005   Lung           China                       Asian              PB       TaqMan                       38     52        26    116    38      46     25    109    0.44   0.133   10
  Weiss              2005   Endometrial    America                     Caucasian          PB       PCR-RFLP                     215    134       22    371    250     148    22    420    0.23   0.987   11
  Blankenburg        2005   Melanoma       German                      Caucasian          PB       PCR-RFLP                     9      100       184   293    18      124    232   374    0.79   0.785   8
  Sanyal             2004   Bladder        Sweden                      Caucasian          PB       PCR-RFLP                     182    109       8     299    173     91     20    284    0.23   0.102   8
  Kumar              2003   Breast         Finland                     Caucasian          PB       PCR-RFLP                     108    96        16    220    182     107    19    308    0.24   0.540   10
  ------------------ ------ -------------- --------------------------- ------------------ -------- ---------------------------- ------ --------- ----- ------ ------- ------ ----- ------ ------ ------- ----

MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium; B-NHL, B cell non-Hodgkin\'s lymphoma; BCL, B cell lymphoma; HNC, head and neck cancer; HCC, hepatocellular carcinoma; HD, Hodgkin's disease; NMSC, non-melanoma skin cancer; OSCC, oral squamous cell carcinoma; BCC, basal cell carcinoma; HB, hospital based; PB, population based; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; AS-PCR, allele-specific PCR.

Meta-analysis results
---------------------

As we can see in [Table 2](#t2){ref-type="table"} and [Figure 2](#f2){ref-type="fig"}, significant between-study heterogeneity was detected under all the genetic models in the overall analysis. Thus, we used random-effect model. After calculating crude odds ratios (ORs) and 95% confidence interval (CIs), we found that *XPG* gene rs17655 G\>C polymorphism was associated with increased overall cancer susceptibility (CC vs. GG: OR=1.10, 95% CI=1.00-1.20, *P*=0.032; CG vs. GG: OR=1.06, 95% CI=1.02-1.11, *P*=0.013; CG+CC vs. GG: OR=1.07, 95% CI=1.02-1.12, *P*=0.004; C vs. G: OR=1.05, 95% CI=1.01-1.09, *P*=0.011). Stratification analysis further indicated that the *XPG* gene rs17655 G\>C polymorphism was associated with increased risk of gastric cancer (CC vs. GG: OR=1.53, 95% CI=1.16-2.01, *P*=0.002; CG vs. GG: OR=1.25, 95% CI=1.02-1.53, *P*=0.030; CG+CC vs. GG: OR=1.32, 95% CI=1.09-1.60, *P*=0.005; C vs. G: OR=1.23, 95% CI=1.06-1.42, *P*=0.005) and colorectal cancer (CG vs. GG: OR=1.30, 95% CI=1.12-1.51, *P*=0.001; CG+CC vs. GG: OR=1.28, 95% CI=1.11-1.48, *P*=0.001; C vs. G: OR=1.16, 95% CI=1.05-1.30, *P*=0.011) ([Supplemental Figure 1](#SD1){ref-type="supplementary-material"}). We also checked the association in Asian (18 studies) and Caucasian (24 studies), among which ethnic groups studies were enriched. Interestingly, we only observed significant association in Asian (CC vs. GG: OR=1.25, 95% CI=1.05-1.49, *P*=0.013; CG vs. GG: OR=1.20, 95% CI=1.06-1.35, *P*=0.002; CG+CC vs. GG: OR=1.21, 95% CI=1.07-1.38, *P*=0.005; C vs. G: OR=1.13, 95% CI=1.03-1.23, *P*=0.005). Moreover, the association remained significant in the subgroups with quality score ≤ 9 (CC vs. GG: OR=1.20, 95% CI=1.04-1.39, *P*=0.015; CG vs. GG: OR=1.09, 95% CI=1.00-1.18, *P*=0.033; CG+CC vs. GG: OR=1.11, 95% CI=1.02-1.21, *P*=0.018; C vs. G: OR=1.07, 95% CI=1.01-1.15, *P*=0.065) and hospital-based studies (CC vs. GG: OR=1.19, 95% CI=1.02-1.39, *P*=0.028; CG vs. GG: OR=1.10, 95% CI=1.01-1.20, *P*=0.032; CG+CC vs. GG: OR=1.12, 95% CI=1.02-1.22, *P*=0.009; C vs. G: OR=1.09, 95% CI=1.02-1.16, *P*=0.007).

###### Meta-analysis of the association between *XPG* gene rs17655 G\>C polymorphism and overall cancer risk.

  --------------- --------- --------------------- ---------- -------------- --------------------- -------------- -- ----------------- ---------- --------- --------------------- ---------- -- --------------------- ----------
  Variables       No. of    Homozygous                       Heterozygous                         Recessive         Dominant                     Allele                                                              
                  studies   CC vs. GG                        CG vs. GG                            CC vs. CG+GG      CG+CC vs. GG                 C vs. G                                                             
                            OR (95% CI)           *P*^het^                  OR (95% CI)           *P*^het^          OR (95% CI)       *P*^het^             OR (95% CI)           *P*^het^      OR (95% CI)           *P*^het^
  All             60        **1.10(1.00-1.20)**   0.001                     **1.06(1.02-1.11)**   0.040             1.04(0.97-1.12)   0.028                **1.07(1.02-1.12)**   0.002         **1.05(1.01-1.09)**   0.000
  Cancer type                                                                                                                                                                                                        
  Gastric         5         **1.53(1.16-2.01)**   0.407                     **1.25(1.02-1.53)**   0.793             1.30(0.93-1.82)   0.131                **1.32(1.09-1.60)**   0.755         **1.23(1.06-1.42)**   0.288
  Breast          11        1.10(0.95-1.27)       0.613                     1.08(0.95-1.22)       0.047             1.04(0.92-1.19)   0.768                1.08(0.95-1.22)       0.036         1.04(0.96-1.14)       0.073
  Colorectal      4         1.24(0.96-1.59)       0.395                     **1.30(1.12-1.51)**   0.395             1.06(0.84-1.34)   0.401                **1.28(1.11-1.48)**   0.554         **1.16(1.05-1.30)**   0.875
  Lymphoma        4         1.13(0.57-2.24)       0.049                     0.98(0.69-1.41)       0.022             1.17(0.66-2.08)   0.110                0.97(0.65-1.46)       0.004         0.98(0.69-1.39)       0.001
  Bladder         6         0.97(0.71-1.33)       0.177                     1.03(0.92-1.16)       0.520             0.93(0.70-1.24)   0.193                1.02(0.91-1.14)       0.588         1.00(0.91-1.09)       0.636
  Lung            6         1.26(0.92-1.73)       0.007                     1.13(0.93-1.37)       0.051             1.12(0.92-1.37)   0.136                1.16(0.94-1.43)       0.011         1.11(0.96-1.28)       0.012
  HNC             3         0.88(0.71-1.09)       0.819                     1.01(0.90-1.14)       0.898             0.90(0.74-1.10)   0.684                0.99(0.88-1.11)       0.944         0.97(0.89-1.06)       0.984
  Others          13        1.09(0.88-1.36)       0.014                     1.04(0.95-1.14)       0.411             1.07(0.87-1.31)   0.014                1.05(0.95-1.15)       0.226         1.05(0.96-1.15)       0.051
  Skin            8         0.96(0.75-1.23)       0.175                     0.97(0.88-1.06)       0.793             0.96(0.79-1.17)   0.254                0.96(0.88-1.05)       0.657         0.97(0.90-1.04)       0.427
  Ethnicity                                                                                                                                                                                                          
  Asian           18        **1.25(1.05-1.49)**   0.003                     **1.20(1.06-1.35)**   0.031             1.10(0.97-1.25)   0.044                **1.21(1.07-1.38)**   0.005         **1.13(1.03-1.23)**   0.002
  Caucasian       24        0.98(0.87-1.10)       0.254                     1.01(0.95-1.06)       0.437             0.97(0.86-1.09)   0.230                1.00(0.95-1.05)       0.575         0.99(0.95-1.04)       0.590
  Quality score                                                                                                                                                                                                      
  \>9             25        0.98(0.90-1.07)       0.872                     1.04(0.99-1.09)       0.341             0.97(0.90-1.05)   0.932                1.03(0.98-1.08)       0.267         1.01(0.98-1.05)       0.447
  ≤9              35        **1.20(1.04-1.39)**   0.000                     **1.09(1.00-1.18)**   0.023             1.10(0.98-1.24)   0.002                **1.11(1.02-1.21)**   0.001         **1.07(1.01-1.15)**   0.000
  Design                                                                                                                                                                                                             
  HB              26        **1.19(1.02-1.39)**   0.002                     **1.10(1.01-1.20)**   0.031             1.09(0.97-1.24)   0.034                **1.12(1.02-1.22)**   0.004         **1.09(1.02-1.16)**   0.003
  PB              31        1.03(0.91-1.17)       0.079                     1.04(0.97-1.10)       0.185             1.00(0.90-1.12)   0.118                1.03(0.97-1.10)       0.069         1.02(0.97-1.07)       0.022
  Mixed           3         1.04(0.91-1.18)       0.376                     1.05(0.97-1.13)       0.690             1.01(0.90-1.14)   0.550                1.04(0.97-1.12)       0.504         1.03(0.97-1.09)       0.431
  --------------- --------- --------------------- ---------- -------------- --------------------- -------------- -- ----------------- ---------- --------- --------------------- ---------- -- --------------------- ----------

HNC, Head and Neck cancer; OR, odds ratio; CI, confidence interval; Het, heterogeneity.

![**Forest plot for the association between the *XPG* rs17655 G\>C polymorphism and overall cancer risk under the dominant model (CG/CC vs. GG).** For each publication, the estimation of OR and its 95% CI was plotted with a box and a horizontal line. The diamonds represented the pooled ORs and 95% CIs.](aging-10-101448-g002){#f2}

Publication Bias
----------------

Symmetry in the funnel plot ([Figure 3](#f3){ref-type="fig"}) suggested that there was no significant publication bias in this meta-analysis (CC vs. GG: *P*=0.808; CG vs. GG: *P*=0.050; CC vs. CG+GG: *P*=0.806; CG+CC vs. GG: *P*=0.047; C vs. G: *P*=0.240).

![Funnel plot for the association between *XPG* gene rs17655 G\>C polymorphism and overall cancer risk under the dominant model (CG/CC vs. GG).](aging-10-101448-g003){#f3}

DISCUSSION
==========

In the current meta-analysis, we estimated the association between the *XPG* gene rs17655 G\>C polymorphism and cancer risk based on 60 eligible case-control studies with a total of 27,098 cancer cases and 30,535 healthy controls. Pooled risk estimates revealed that this polymorphism was significantly associated with an increased risk of overall cancer, especially with the risk of gastric cancer and colorectal cancer.

The etiology of cancer is multifactorial \[[@r1]\]. Abnormal accumulation of DNA mutations caused by a variety of factors might eventually trigger carcinogenic process \[[@r68]\]. Thus, properly repairing DNA damages in time to ensure genome stability and integrity is essential to prevent cancer. NER system includes two pathways: global genome repair and transcription-coupled repair, in both of which XPG plays a crucial role \[[@r6]--[@r8]\]. *XPG* gene, one of the eight vital genes in the NER pathway, is responsible for recognizing and excising DNA lesions on the 3' side \[[@r3],[@r4]\]. Loads of SNPs have been identified in the *XPG* gene over the past decades, among which the rs17655 polymorphism has revoked great attention for its association with cancer risk. The rs17655 polymorphism, leading to the replacement of aspartate with histidine at codon 1104 in ERCC5 protein, may cause an alteration in the protein function, thereby likely affecting DNA repair ability, genome integrity, and cancer predisposition.

Numerous studies were performed to explore the association between the rs17655 polymorphism and the risk of various types of cancer. Feng et al. \[[@r22]\] carried out a study in 2016 to investigate the roles of three SNPs (rs2094258, rs751402 and ra17655) in the *XPG* gene, consisting of 177 patients and 237 controls. They found that the rs17655 polymorphism was associated with an increased risk of gastric cancer. This association was reconfirmed in different types of cancer, including breast cancer by Hsu et al. \[[@r29]\] with 401 cases and 531controls, colorectal carcinoma by Du et al. \[[@r20]\] with 878 cases and 884 controls, lung cancer by Chang et al. \[[@r17]\] with 255 cases and 280 controls, as well as cancer of other types. However, opposite results were also frequently reported. A population-based case-control study containing 196 gastric cases and 397 controls subjects conducted by Hussain et al. \[[@r31]\] revealed that the *XPG* rs17655 polymorphism might be associated with reduced gastric cancer risk. Additionally, Ruiz-Cosano et al. \[[@r68]\] reported that this polymorphism did not seem to play a major role in lymphoma susceptibility after studying 213 cases and 214 controls. Ma et al. \[[@r62]\] selected 320 cases and 294 controls and found that the rs17655 polymorphism might not confer susceptibility to breast cancer after adjusting for potential confounding factors. Several meta-analyses were also conducted, and unfortunately the results were still inconsistent \[[@r88]--[@r91]\]. As contradictory results were produced, we performed this meta-analysis to draw a more precise conclusion by including larger sample size and different cancer types from 60 studies. Our result indicated that this polymorphism may increase the risk of overall cancer, especially the risk of gastric cancer and colorectal cancer. The biological function of the rs17655 remains obscure. This polymorphism has been intensively studied for its association with cancer risk as a tagger. It was predicated to be a harmful variant by a sequence homology-based tool \[[@r92]\]. Moreover, its functional potential was further confirmed by SIFT algorithms (scale invariant feature transform) and SNPs3D tools (<http://compbio.cs.queensu.ca/F-SNP/>) \[[@r93]\]; however, solid *in vitro* and *in vivo* data are needed to elucidate biological function of this variant.

There are advantages that strengthened the robustness of our findings. First, we searched five databases to include most of the publications written in English or Chinese. The large sample size provided adequate statistical power. Second, stratified analyses were performed by cancer type, quality score, and source of control. Third, we used the Begg's funnel plot and Egger's linear regression test to assess the possible publication bias.

However, several limitations still existed in this meta-analysis. Firstly, selection bias might occur because only publications written in English or Chinese were included. Researches in other languages were missed. Secondly, the number of individual studies for some cancer types, like HNC and prostate cancer (\<5 studies), may be inadequate. Third, more than half of included studies had relative low quality scores (≤ 9). Our results should be interpreted cautiously. Further studies with high quality scores are needed to verify the real association.

Additionally, age, sex, living habits, virus infections or some environmental factors may also influence cancer risk. Our findings based on unadjusted estimates for lack of access to original data might suffer from potential confounding bias. Therefore, the results should be interpreted with caution. Finally, lack of biological evidence of the implication of the rs17655 polymorphism in cancer is also a drawback of the study. Mechanistic studies of the rs17655 polymorphism with cancer should be performed in the future.

In conclusion, this meta-analysis suggests that the *XPG* rs17655 G\>C polymorphism is significantly associated with an increased overall cancer risk, especially with the risk of gastric cancer and colorectal cancer. Moreover, large-scale, well-designed studies in different cancers should be conducted to corroborate our findings.

MATERIALS AND METHODS
=====================

Publication search
------------------

We searched for relevant articles using the following terms: "*ERCC5* or *XPG*", "polymorphism or variant", and "cancer or carcinoma or neoplasm or malignance" in PubMed, EMBASE, CNKI, WANFANG, and Vip databases (the last search was performed on June 17, 2016). We also manually searched the references of the retrieved publications for additional relevant eligible studies.

Inclusion and Exclusion criteria
--------------------------------

The publications contained in the meta-analysis had to meet the following criteria: (1) the study was only written in English or Chinese; (2) the study investigated the association between the *XPG* gene rs17655 polymorphism and the risk of one or more types of cancer; (3) case-control study. If studies had overlapping subjects, the publication including the largest number of individuals were selected.

Exclusion criteria were as follows (1) the study did not report sufficient genotype data to calculate odds ratio (OR) and 95% confidence interval (CI); (2) the study included survival data only. (3) the genotype frequencies of the rs17655 G\>C and other polymorphisms were deviated from Hardy-Weinberg equilibrium (HWE) in the controls.

Data Extraction and quality assessment
--------------------------------------

Two investigators (Chen SS and Zhao J) extracted the following information from each publication independently: first author, publication year, cancer type, country of origin, race, genotyping method, source of controls (hospital-based, population-based and mixed), the genotype counts of cases and controls for the rs17655 G\>C polymorphism. We also calculated the score of each publication based on the quality score assessment as described before \[[@r94]\]. All contradictory information was discussed when necessary.

Statistical analysis
--------------------

We evaluated crude ORs and 95% CIs to assess the association between *XPG* rs17655 G\>C polymorphism and overall cancer risk under the homozygous (CC vs. GG), heterozygous (CG vs. GG), recessive (CC vs. CG+GG), dominant (CG+CC vs. GG), and allele contrast (C vs. G) models. We carried out stratification analyses by cancer type (if one cancer type were investigated in less than three studies, we termed this type as "others"), score (\>9 and ≤9), and study design (if a study contained both hospital-based controls and population-based subjects, we termed the study design as "mixed"). We also calculated between-study heterogeneity using the Chi square-based Q-test. When *P*\>0.1 indicating lack of heterogeneity, a fixed-effect model was adopted. Otherwise, a random-effect model would be applied \[[@r94]\]. The potential publication bias was evaluated by Begg's funnel plot \[[@r95]\] and Egger's linear regression test \[[@r96]\]. All of the *P* values were two-tailed. *P*\<0.05 was considered statistically significant. All data analyses were performed by the STATA software (Version 12.0; Stata Corporation, College Station, TX).
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